Haemonetics (HAE) Cost of Revenue (2016 - 2025)
Haemonetics (HAE) has 17 years of Cost of Revenue data on record, last reported at $136.6 million in Q4 2025.
- For Q4 2025, Cost of Revenue fell 11.88% year-over-year to $136.6 million; the TTM value through Dec 2025 reached $535.9 million, down 16.5%, while the annual FY2025 figure was $611.9 million, 0.91% down from the prior year.
- Cost of Revenue reached $136.6 million in Q4 2025 per HAE's latest filing, up from $132.6 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $167.4 million in Q1 2024 and bottomed at $117.4 million in Q4 2021.
- Average Cost of Revenue over 5 years is $140.6 million, with a median of $141.4 million recorded in 2021.
- Peak YoY movement for Cost of Revenue: grew 20.95% in 2022, then decreased 19.91% in 2025.
- A 5-year view of Cost of Revenue shows it stood at $117.4 million in 2021, then rose by 24.91% to $146.6 million in 2022, then grew by 8.04% to $158.4 million in 2023, then dropped by 2.14% to $155.0 million in 2024, then decreased by 11.88% to $136.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Cost of Revenue were $136.6 million in Q4 2025, $132.6 million in Q3 2025, and $129.2 million in Q2 2025.